Emmaus Life Sciences, Inc. (EMMA) stock
EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05−0.01 (-14.38%)
Close on Oct 19, 2026Market cap $6.03MP/E –Yield –
Emmaus Life Sciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Emmaus Life Sciences's ebitda for the twelve months ending Jun 30, 2026 was $4.61M. For fiscal 2025 it was $270.00K. The highest annual figure on record is $3.57M in fiscal 2023.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $270.00K | – |
| FY2024 | Dec 31, 2024 | -$1.87M | -152.4% |
| FY2023 | Dec 31, 2023 | $3.57M | – |
| FY2022 | Dec 31, 2022 | -$6.53M | – |
| FY2021 | Dec 31, 2021 | -$6.07M | -21775.0% |
| FY2020 | Dec 31, 2020 | $28.00K | – |
| FY2019 | Dec 31, 2019 | -$4.44M | – |
| FY2017 | Sep 30, 2017 | -$7.05M | – |
| FY2016 | Sep 30, 2016 | -$3.76M | – |
| FY2015 | Sep 30, 2015 | -$2.64M | – |
| FY2014 | Sep 30, 2014 | -$3.81M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $3.81M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$808.00K | -197.8% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $901.00K | +53.2% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $710.00K | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$552.00K | -140.6% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $826.00K | +2481.3% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $588.00K | -82.4% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$2.73M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $1.36M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $32.00K | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $3.34M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$1.16M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$1.41M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$648.00K | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$1.43M | -386.5% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$3.05M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$4.95M | -1416.5% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$17.00K | -173.9% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $498.00K | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$1.60M | -239.3% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $376.00K | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $23.00K | -82.8% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$1.52M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $1.15M | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$3.31M | – |
| Q3 FY2019CQ3 2018 | Jun 30, 2019 | $134.00K | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$2.68M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$1.54M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$1.41M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$1.43M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$1.64M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -$808.00K | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | -$688.70K | – |
| Q1 FY2016CQ4 2015 | Dec 31, 2015 | -$623.30K | – |
| Q4 FY2015CQ3 2015 | Sep 30, 2015 | -$532.00K | – |
| Q3 FY2015CQ2 2015 | Jun 30, 2015 | -$554.40K | – |
| Q2 FY2015CQ1 2015 | Mar 31, 2015 | -$777.90K | – |
| Q1 FY2015CQ4 2014 | Dec 31, 2014 | -$777.00K | – |
See a number that looks wrong?